Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 + Gemtuzumab Ozogamicin in Older AML
NCT03878927Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (3 cohorts), sponsored by Weill Cornell Medicine. Primary endpoint: Feasible dose of Gemtuzumab Ozogamicin (GO) in combination with CPX-351 at 5 years. Started Aug 2019; status: terminated.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03878927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878927.